EMA seeks stakeholder input on new reflection paper to reduce and replace non‑human primate use in medicines safety testing through 3Rs approaches.

EMA public consultation on non‑human primate use in safety testing

Non-human primate hand via pickpik.com (CC0)

The European Medicines Agency (EMA) has launched a public consultation on a draft “Reflection paper on non-human primates in safety testing of human medicinal products and opportunities for 3Rs implementation”.

The reflection paper provides an overview of the scientific and regulatory considerations for using non‑human primates (NHPs) in the safety testing of human medicinal products. It reviews current uses, highlights existing flexibility in applying the 3Rs principles (Replacement, Reduction and Refinement), and points to emerging alternatives that could further reduce or replace NHP use in the future.

NHPs should be used for regulatory safety testing only as a last resort. The document outlines current opportunities to reduce, refine or replace their use in pharmaceutical development and describes scientific advances that may soon gain broader regulatory acceptance.

Progress in novel, including non‑animal, approaches is scientifically and ethically essential and will depend on continued innovation, collaboration and proactive regulatory engagement.

The draft document is open for consultation, and stakeholders can provide input until 31 January 2026 via the EMA website: Non-human primates in safety testing of human medicinal products and opportunities for 3Rs implementation – scientific guideline.

News & Updates

You might also be interested in

Radka Kaneva and Petia Stratieva, Sofia, March 2026

“National Mirror Groups are essentially a bridge — bringing European developments, standards and opportunities to clinicians and researchers.”

ERDERA interviews Prof. Radka Kaneva and Dr Petia Stratieva, two leading members of Bulgaria’s National Mirror Group (NMG), to explore how the country is working to align its rare disease ecosystem with European developments.
Gdańsk - Medical University of Gdańsk

From Hyderabad to Gdansk: collaborative diagnostic efforts that bridge research and clinical practice to shorten patients’ path to answers

ERDERA joins the Wilhelm Foundation and the Gdansk Medical University and Clinical Centre to strengthen phenotype‑led diagnosis for people living with undiagnosed conditions
European Parliament

European Parliament draft report urges a binding EU rare disease action framework

A legislative own initiative file in the Parliament’s new public health committee sets out what an EU “rare disease action framework” could look like — and why it could change how Europe measures progress for patients.
European Parliament Photograph

New European Parliament study maps options for an EU rare disease action plan

European Parliament research service assessment, published in February 2026, identifies 31 measures that could form an EU rare disease action plan, highlighting European Reference Networks and cross-border collaboration including ERDERA as drivers of EU added value.

ERDERA's

search form